More recently, in the treatment of metastatic breast cancer, selective small molecule CDK4/6 inhibitors have also become increasingly effective, such as palbociclib, ribociclib and abemaciclib, which have been developed in metastatic luminal breast cancer (Cadoo et al., 2014). This evidence concerns the gene CDK4 and breast carcinoma.